HOUSTON — Cannabidiol (CBD), one of the active cannabinoids in cannabis, continues to be a hot treatment topic among epilepsy experts, and this will be reflected by presentations of related research here at the American Epilepsy Society (AES) 2016 Annual Meeting.
Some 21 scientific presentations involving CBD will be released and discussed at the meeting, which takes place December 2–6, said AES President Michael D. Privitera, MD, professor, neurology, and director, Epilepsy Center, University of Cincinnati, Ohio.
This includes the first full reports of two of the three completed randomized controlled trials of cannabidiol product Epidiolex (GW Pharmaceuticals), he said.
“These are the first ever reports of placebo-controlled trials in epilepsy with cannabidiol, and I believe the first in any therapeutic area,” he told Medscape Medical News.
GW Pharmaceuticals released topline results of its three trials in a press release earlier this year. “All three studies were positive,” said Dr Privitera, adding that the company’s stock “skyrocketed” afterward.
“However, all they said was that ‘the study was positive for the primary outcome’ and provided no other details,” he said.
More details of these studies will be revealed at the meeting. One of the studies included patients with Dravet syndrome, and the other enrolled patients with Lennox-Gastaut syndrome (LGS). The second LGS study was not completed in time to be submitted for the meeting, he noted.
Unlike THC (tetrahydrocannabinol), CBD is not psychoactive. In addition to possible seizure control, CBD is believed to have a wide range of other medical applications.
Unlike past meetings, this one will have an increased focus on precision medicine, says Peter B. Crino, chair, Department of Neurology, University of Maryland School of Medicine, Baltimore, who helped design the scientific program.
“This is targeted therapies, so not just using blockbuster drugs to fit everybody, but